Simeglutide is more effective in the treatment of diabetes, but this drug is only suitable for adults with type 2 diabetes, and the specific effect is likely to vary due to individual differences. Simeglutide is suitable for patients with type 2 diabetes mellitus whose diabetes mellitus is not well treated with sulfonylureas or metformin on the basis of exercise and dietary control. Clinical trials have shown that this drug can reduce fasting and postprandial glucose concentrations, and reduce the chances of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and other cardiovascular diseases among patients with type 2 diabetes mellitus. Common adverse reactions to simethicone include nausea, vomiting, and diarrhea, which are mild to moderate and of short duration. Note that this drug is contraindicated in people who are allergic to the active ingredient or excipients of this drug, people with a personal history or family history of medullary thyroid carcinoma, people with type 2 multiple endocrine neoplasia syndrome, people with type 1 diabetes mellitus, and people with diabetic ketoacidosis. Simeglutide is not an insulin replacement drug, patients should not use the drug privately, but must be directed by a professional doctor.